Total Payments
$72,299
2024 Payments
$8,050
Companies
3
Transactions
63

Payment Breakdown by Category

Consulting$45,850 (63.4%)
Research$26,449 (36.6%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $45,850 42 63.4%
Unspecified $26,449 21 36.6%

Payments by Type

General
$45,850
42 transactions
Research
$26,449
21 transactions

Top Paying Companies

Company Total Records Latest Year
Amgen Inc. $45,850 42 $0 (2024)
Regeneron Pharmaceuticals, Inc. $17,366 17 $0 (2020)
Novartis Pharma AG $9,083 4 $0 (2021)

Payment History by Year

Year Amount Transactions Top Company
2024 $8,050 6 Amgen Inc. ($8,050)
2023 $8,050 7 Amgen Inc. ($8,050)
2022 $7,000 6 Amgen Inc. ($7,000)
2021 $10,562 7 Amgen Inc. ($7,700)
2020 $15,601 12 Amgen Inc. ($6,300)
2019 $8,750 10 Amgen Inc. ($4,900)
2018 $14,286 15 Regeneron Pharmaceuticals, Inc. ($10,436)

All Payment Transactions

63 individual payment records from CMS Open Payments — Page 1 of 3

Date Company Product Nature Form Amount Type
12/17/2024 Amgen Inc. Consulting Fee Cash or cash equivalent $1,400.00 General
12/03/2024 Amgen Inc. Aimovig (Biological) Consulting Fee Cash or cash equivalent $1,050.00 General
Category: Neuroscience
09/17/2024 Amgen Inc. Repatha (Biological) Consulting Fee Cash or cash equivalent $2,100.00 General
Category: Cardiology
06/11/2024 Amgen Inc. Consulting Fee Cash or cash equivalent $1,400.00 General
05/28/2024 Amgen Inc. Aimovig (Biological) Consulting Fee Cash or cash equivalent $1,050.00 General
Category: Neuroscience
03/25/2024 Amgen Inc. Repatha (Biological) Consulting Fee Cash or cash equivalent $1,050.00 General
Category: Cardiology
12/19/2023 Amgen Inc. Aimovig (Biological) Consulting Fee Cash or cash equivalent $1,400.00 General
Category: Neuroscience
11/08/2023 Amgen Inc. Consulting Fee Cash or cash equivalent $1,400.00 General
09/27/2023 Amgen Inc. Repatha (Biological) Consulting Fee Cash or cash equivalent $1,400.00 General
Category: Cardiology
06/19/2023 Amgen Inc. Aimovig (Biological) Consulting Fee Cash or cash equivalent $1,050.00 General
Category: Neuroscience
06/05/2023 Amgen Inc. Consulting Fee Cash or cash equivalent $700.00 General
03/23/2023 Amgen Inc. Repatha (Biological) Consulting Fee Cash or cash equivalent $1,400.00 General
Category: Cardiology
03/15/2023 Amgen Inc. Consulting Fee Cash or cash equivalent $700.00 General
12/15/2022 Amgen Inc. Aimovig (Biological) Consulting Fee Cash or cash equivalent $1,050.00 General
Category: Neuroscience
10/07/2022 Amgen Inc. Repatha (Biological) Consulting Fee Cash or cash equivalent $1,400.00 General
Category: Cardiology
08/26/2022 Amgen Inc. Consulting Fee Cash or cash equivalent $1,050.00 General
06/13/2022 Amgen Inc. Aimovig (Biological) Consulting Fee Cash or cash equivalent $1,400.00 General
Category: Neuroscience
03/30/2022 Amgen Inc. Repatha (Biological) Consulting Fee Cash or cash equivalent $1,050.00 General
Category: Cardiology
02/09/2022 Amgen Inc. Aimovig (Biological) Consulting Fee Cash or cash equivalent $1,050.00 General
Category: Neuroscience
11/04/2021 Amgen Inc. Aimovig (Biological) Consulting Fee Cash or cash equivalent $1,400.00 General
Category: Neuroscience
09/27/2021 Amgen Inc. Repatha (Biological) Consulting Fee Cash or cash equivalent $1,400.00 General
Category: Cardiology
07/27/2021 Amgen Inc. Aimovig (Biological) Consulting Fee Cash or cash equivalent $1,400.00 General
Category: Neuroscience
05/26/2021 Amgen Inc. Aimovig (Biological) Consulting Fee Cash or cash equivalent $1,400.00 General
Category: Neuroscience
05/06/2021 Amgen Inc. Repatha (Biological) Consulting Fee Cash or cash equivalent $700.00 General
Category: Cardiology
04/07/2021 Novartis Pharma AG AIMOVIG (Biological) Cash or cash equivalent $2,862.00 Research
Study: CAMG334A2304 • Category: NEUROSCIENCE

Research Studies & Clinical Trials

Study Name Company Amount Records
A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REGN475 IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP Regeneron Pharmaceuticals, Inc. $17,366 17
CAMG334A2304 Novartis Pharma AG $9,083 4

About Barry Davis

Barry Davis is a Public Health & General Preventive Medicine healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/24/2018. The National Provider Identifier (NPI) number assigned to this provider is 1578047635.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Barry Davis has received a total of $72,299 in payments from pharmaceutical and medical device companies, with $8,050 received in 2024. These payments were reported across 63 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($45,850).

Practice Information

  • Specialty Public Health & General Preventive Medicine
  • Location Houston, TX
  • Active Since 09/24/2018
  • Last Updated 07/31/2023
  • Taxonomy Code 2083P0901X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1578047635

Products in Payments

  • Repatha (Biological) $23,450
  • Aimovig (Biological) $15,750
  • AMG334A_AIMOVIG_NEUROSCIENCE (Biological) $6,221
  • AIMOVIG (Biological) $2,862

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Public Health & General Preventive Medicine Doctors in Houston